YY1-regulated lncRNA SOCS2-AS1 suppresses HCC cell stemness and progression via miR-454-3p/CPEB1
Biochemical and Biophysical Research Communications · 2023
DOI: 10.1016/j.bbrc.2023.08.056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Feng Zhong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, MicroRNAs, Liver Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Southern University of Science and Technology.
Abstract (Originalsprache)
BACKGROUND: Cancer stem cells are one fundamental reason for the high recurrence rate of hepatocellular carcinoma (HCC) and its resistance to treatment. This study explored the mechanism by which SOCS2-AS1 affects HCC cell stemness. METHODS: Stem cells of HCC cell lines Huh7 and SNU-398 were sorted as NANOG-positive by flow cytometry. Stem cell sphere formation ability was detected. Stem cell viability, migration, invasion, and apoptosis were assessed by colony formation assays, Transwell assays, wound-healing assays, and TUNEL assays, respectively. The binding sites for SOCS2-AS1, miR-454-3p, miR-454-3p, and CPEB1 mRNA were assessed by dual-luciferase reporter assays. Quantitative real-time PCR (qPCR) and Western blot studies were performed to evaluate gene expression levels. ChIP and EMSA assays were conducted to confirm that YY1 binds with the SOCS2-AS1 promoter. A subcutaneous xenograft model was used to verify results in vivo. Tumor tissues were analyzed by H&E and TUNEL staining. RESULTS: SOCS2-AS1 was expressed at low levels in NANOG+ HCC stem cells, and HCC patients with a high level of SOCS2-AS1 expression had a higher survival rate. SOCS2-AS1 inhibited HCC cell stemness, migration, and invasion, and increased the cisplatin sensitivity of HCC cells by regulating miR-454-3p/CPEB1. YY1 was confirmed as a transcription factor of SOCS2-AS1, and served to inhibit SOCS2-AS1 transcription. YY1 knockdown suppressed HCC stemness via SOCS2-AS1. The role of SOCS2-AS1 was confirmed in a subcutaneous xenograft model, and SOCS2-AS1 overexpression enhanced the inhibitory effect of cisplatin on HCC in vivo. CONCLUSIONS: YY1-regulated lncRNA SOCS2-AS1 suppresses HCC cell stemness and progression via miR-454-3p/CPEB1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China.
- Vascular and Endovascular Surgery, Shenzhen Samii Medical Center, Shenzhen, Guangdong, 518118, China. Electronic address: wyxboy@sina.com.
Förderung
- Southern University of Science and Technology
Zitieren
APA
Zhong, F., & Wang, Y. (2023). YY1-regulated lncRNA SOCS2-AS1 suppresses HCC cell stemness and progression via miR-454-3p/CPEB1. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.08.056
Vancouver
Zhong F, Wang Y. YY1-regulated lncRNA SOCS2-AS1 suppresses HCC cell stemness and progression via miR-454-3p/CPEB1. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.08.056
BibTeX
@article{Zhong2023,
author = {Zhong, Feng and Wang, Yuanxi},
title = {YY1-regulated lncRNA SOCS2-AS1 suppresses HCC cell stemness and progression via miR-454-3p/CPEB1},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
doi = {10.1016/j.bbrc.2023.08.056}
}
EUVIMED